TVRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TVRD is not a good buy right now for an impatient trader. The prevailing trend is bearish (downtrend structure with weakening momentum), there are no Intellectia buy signals today, no fresh news catalysts, and the options market is priced for extreme volatility—more consistent with speculative trading than a clean long entry. I would avoid new buys here; if already holding, I would sell/step aside rather than wait for a better setup.
Trend/Momentum: Bearish. Moving averages are stacked negatively (SMA_200 > SMA_20 > SMA_5), implying an established downtrend. MACD histogram is below zero (-0.0327) and expanding negatively, suggesting downside momentum is still building.
Momentum/Oversold: RSI_6 at 28 is near oversold conditions, which can create short bounces, but it is not a reliable buy signal by itself when trend and MACD are still deteriorating.
Levels: Pivot 4.377 is overhead; price (3.9–3.97) is below pivot, keeping bias bearish. Key supports: S1 3.976 (very nearby, already being tested) and S2 3.728 (next downside). Resistances: R1 4.778 then R2 5.025. A buy would look better only after reclaiming/holding above pivot (4.377) with improving MACD, which is not present now.
Price action context: Regular session was up (+1.79%) but post-market is down (-1.76%), consistent with fragile sentiment.
No news catalysts in the past week.
Options market shows bullish skew (low OI put/call) which can sometimes precede short-term pops.
Pattern-based forecast suggests modest upside probabilities (60% chance of small gains over 1D/1W/1M), but magnitudes are limited (~1.66% next day).
with room to fall toward S2 ~3.728 if support breaks.
Latest quarter: 2025/Q3. The company remains pre-revenue (Revenue = 0, 0% YoY). Net income was -$5.53M (slightly improved YoY by ~0.25%), but EPS deteriorated to -0.59 (down ~72.43% YoY). Overall, fundamentals reflect an early-stage biotech profile with ongoing losses and worsening per-share earnings in the latest quarter.
No analyst rating or price target change data was provided, so a Wall Street pro/con consensus cannot be reliably summarized from the dataset. Based on available data only, there is no visible analyst-driven catalyst supporting an immediate buy.
